Regulation of IKKbeta by MiR-199a Affects NF-kappaB Activity in Ovarian Cancer Cells

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2008 Apr 15

PMID 18408758

Citations 174

Authors

R Chen

A B Alvero

D A Silasi

M G Kelly

S Fest

I Visintin

A Leiser

P E Schwartz

T Rutherford

G Mor

Affiliations

Soon will be listed here.

Abstract

Cancer progression is an abnormal form of tissue repair characterized by chronic inflammation. IkappaB kinase-beta (IKKbeta) required for nuclear factor-kappaB (NF-kappaB) activation plays a critical role in this process. Using EOC cells isolated from malignant ovarian cancer ascites and solid tumors, we identified IKKbeta as a major factor promoting a functional TLR-MyD88-NF-kappaB pathway that confers to EOC cell the capacity to constitutively secrete proinflammatory/protumor cytokines and therefore promoting tumor progression and chemoresistance. Furthermore, we describe for the first time the identification of the microRNA hsa-miR-199a as a regulator of IKKbeta expression. Our study describes the property of ovarian cancer cells to enhance the inflammatory microenvironment as a result of the expression of an active IKKbeta pathway. Identification of these markers in patients' tumor samples may facilitate the adequate selection of treatment and open new venues for the development of effective therapy for chemoresistant ovarian cancers.

Citing Articles

Ascitic Shear Stress Activates GPCRs and Downregulates Mucin 15 to Promote OvarianCancer Malignancy.

Mehta G, Horst E, Cotter L, Bonini M, Novak C, Treacher N Res Sq. 2024; .

PMID: 39483899 PMC: 11527234. DOI: 10.21203/rs.3.rs-5160301/v1.

Application and prospect of the therapeutic strategy of inhibiting cellular senescence combined with pro-regenerative biomaterials in regenerative medicine.

Li Q, Wang Z, Shi N, Qi Y, Yao W, Yu J Smart Med. 2024; 2(4):e20230030.

PMID: 39188301 PMC: 11235619. DOI: 10.1002/SMMD.20230030.

Non-coding RNAs as therapeutic targets in cancer and its clinical application.

Leng X, Zhang M, Xu Y, Wang J, Ding N, Yu Y J Pharm Anal. 2024; 14(7):100947.

PMID: 39149142 PMC: 11325817. DOI: 10.1016/j.jpha.2024.02.001.

Integrated miRNA Profiling of Extracellular Vesicles from Uterine Aspirates, Malignant Ascites and Primary-Cultured Ascites Cells for Ovarian Cancer Screening.

Skryabin G, Komelkov A, Zhordania K, Bagrov D, Enikeev A, Galetsky S Pharmaceutics. 2024; 16(7).

PMID: 39065600 PMC: 11280431. DOI: 10.3390/pharmaceutics16070902.

MiR-199a-5p Decreases Esophageal Cancer Cell Proliferation Partially through Repression of Jun-B.

Phatak P, Tulapurkar M, Burrows W, Donahue J Cancers (Basel). 2023; 15(19).

PMID: 37835506 PMC: 10571772. DOI: 10.3390/cancers15194811.

References

Greten F, Eckmann L, Greten T, Park J, Li Z, Egan L . IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004; 118(3):285-96. DOI: 10.1016/j.cell.2004.07.013. View

Balkwill F, Coussens L . Cancer: an inflammatory link. Nature. 2004; 431(7007):405-6. DOI: 10.1038/431405a. View

Li Q, Van Antwerp D, Mercurio F, Lee K, Verma I . Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science. 1999; 284(5412):321-5. DOI: 10.1126/science.284.5412.321. View

Yang J, Richmond A . Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res. 2001; 61(12):4901-9. View

Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y . Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med. 2005; 11(11):1173-9. DOI: 10.1038/nm1315. View

Luo J, Kamata H, Karin M . IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest. 2005; 115(10):2625-32. PMC: 1236696. DOI: 10.1172/JCI26322. View

Nakanishi C, Toi M . Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005; 5(4):297-309. DOI: 10.1038/nrc1588. View

Kelly M, Alvero A, Chen R, Silasi D, Abrahams V, Chan S . TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006; 66(7):3859-68. DOI: 10.1158/0008-5472.CAN-05-3948. View

Maeda S, Kamata H, Luo J, Leffert H, Karin M . IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell. 2005; 121(7):977-90. DOI: 10.1016/j.cell.2005.04.014. View

10.

Rothwarf D, Karin M . The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE. 2002; 1999(5):RE1. DOI: 10.1126/stke.1999.5.re1. View

11.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C . Cancer statistics, 2006. CA Cancer J Clin. 2006; 56(2):106-30. DOI: 10.3322/canjclin.56.2.106. View

12.

Romieu-Mourez R, Seldin D, Traish A, Mercurio F, Sonenshein G . Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer. Cancer Res. 2001; 61(9):3810-8. View

13.

Leung C, Grill S, Lam W, Gao W, Sun H, Cheng Y . Eriocalyxin B inhibits nuclear factor-kappaB activation by interfering with the binding of both p65 and p50 to the response element in a noncompetitive manner. Mol Pharmacol. 2006; 70(6):1946-55. DOI: 10.1124/mol.106.028480. View

14.

Greten F, Karin M . The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. 2004; 206(2):193-9. DOI: 10.1016/j.canlet.2003.08.029. View

15.

Hu M, Lee D, Xia W, Golfman L, Ou-Yang F, Yang J . IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell. 2004; 117(2):225-37. DOI: 10.1016/s0092-8674(04)00302-2. View

16.

ODwyer P, Moyer J, Suffness M, Harrison Jr S, Cysyk R, Hamilton T . Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. Cancer Res. 1994; 54(3):724-9. View

17.

Duan Z, Lamendola D, Penson R, Kronish K, Seiden M . Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells. Cytokine. 2002; 17(5):234-42. DOI: 10.1006/cyto.2001.1008. View

18.

Flick M, OMalley D, Rutherford T, Rodov S, Kamsteeg M, Hao X . Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients. J Soc Gynecol Investig. 2004; 11(4):252-9. DOI: 10.1016/j.jsgi.2003.11.003. View

19.

Liu B, Park E, Zhu F, Bustos T, Liu J, Shen J . A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas. Proc Natl Acad Sci U S A. 2006; 103(46):17202-7. PMC: 1859910. DOI: 10.1073/pnas.0604481103. View

20.

Balkwill F . Cancer and the chemokine network. Nat Rev Cancer. 2004; 4(7):540-50. DOI: 10.1038/nrc1388. View